Imdur Extended-Release Tablets

The once-daily extended-release format shapes the decision

The release profile is the most important distinction when comparing Imdur with other nitrate medicines. Imdur is an extended-release tablet containing isosorbide mononitrate and is taken orally on a once-daily schedule. Its formulation releases the active ingredient gradually rather than delivering the whole dose immediately. This supports a regular prevention routine but does not make Imdur suitable for rapid relief of chest pain that has already begun.

This distinction affects both product selection and day-to-day use. A person prescribed a shorter-acting nitrate or several doses across the day should not substitute Imdur simply because the active ingredient or medicine class appears similar. Conversely, someone whose treatment plan specifies extended-release isosorbide mononitrate should confirm that the selected strength and quantity match that plan. The medicine, release type, strength and schedule all matter; matching only the word "nitrate" is not enough.

Extended-release tablets also need formulation-specific handling. They should not be crushed or chewed because doing so may interfere with controlled release. Whether a particular tablet may be divided depends on the exact product information and the prescriber's directions, so it is safer not to split a tablet unless the instructions for that strength specifically permit it.

Imdur's role among nitrate medicines

Imdur is a nitrate vasodilator used for the prophylactic treatment of angina pectoris in adults. In practical terms, it is taken regularly to reduce the likelihood or frequency of angina episodes. It is not a rescue medicine and should not be expected to stop an acute attack immediately.

That role differs from a short-acting nitrate such as Nitroglycerin, commonly called glyceryl trinitrate in Australia, which may be prescribed for rapid relief of an angina episode. Some people have both a long-acting preventive medicine and a separate short-acting medicine, but each has its own directions. Imdur should not replace an acute-relief medicine specified in a person's angina action plan.

The active ingredient is isosorbide mononitrate. Imdur is not the same product as isosorbide dinitrate, even though both belong to the nitrate class, and release schedules can also differ between brands of isosorbide mononitrate. These distinctions should be checked before selecting a strength or pack.

Who may consider Imdur extended-release tablets?

Imdur may be considered for an adult with diagnosed angina who has been assessed by a prescriber and needs regular preventive treatment. It is not a general treatment for unexplained chest discomfort, and it should not be selected solely because a person has high blood pressure or coronary risk factors. New, severe or changing chest pain requires prompt medical assessment rather than self-selection of a preventive nitrate.

The decision should take account of several product-specific and personal factors:

• whether the treatment goal is daily prevention rather than immediate relief of an attack;
• whether the prescribed medicine is specifically extended-release isosorbide mononitrate;
• the prescribed strength, timing and quantity;
• current medicines that may also lower blood pressure or interact with nitrates;
• previous dizziness, fainting, severe headache or low blood pressure with nitrate treatment;
• pregnancy, breastfeeding or plans for pregnancy; and
• the ability to follow a consistent once-daily routine without crushing or chewing the tablet.

Safety and effectiveness in children have not been established. Australian product information also advises that use during pregnancy should occur only when the treating doctor considers it essential. It is not known whether isosorbide mononitrate passes into breast milk, so breastfeeding requires individual clinical advice.

How does isosorbide mononitrate work in daily use?

Isosorbide mononitrate produces nitrate-related vasodilation. It relaxes vascular smooth muscle, particularly in the venous circulation, which reduces the amount of blood returning to the heart and lowers the heart's workload and oxygen demand. This is the basis of its preventive antianginal effect.

The extended-release matrix delivers the medicine gradually across the day after a single daily dose. The schedule is designed to provide useful daytime coverage while avoiding continuous high nitrate exposure around the clock. Continuous exposure can contribute to nitrate tolerance, in which the medicine becomes less effective. For that reason, changing the timing, adding extra doses or combining nitrate products without medical advice can undermine the intended dosing pattern as well as increase adverse effects.

A once-daily schedule may be simpler than a multiple-dose routine, but convenience should not override the prescribed formulation. Immediate-release isosorbide mononitrate, isosorbide dinitrate and extended-release Imdur are not automatically interchangeable dose for dose.

A reliable daily routine

Imdur works as preventive treatment when it is taken consistently, not only on days when exertion is expected. The product information and prescription directions should take priority, but a practical routine usually includes the following steps:

1. Take the prescribed dose once daily at the directed time, commonly in the morning.
2. Swallow the tablet with water and do not crush or chew it.
3. Do not divide the tablet unless the directions for the exact strength say it may be divided.
4. Keep the timing consistent from day to day, including whether it is taken with food.
5. If a dose is missed, follow the product information or seek advice rather than taking two doses together.
6. Do not stop long-term nitrate treatment abruptly unless a clinician has advised how to do so.

Headache is common when nitrate treatment begins and may lessen as the body adjusts. Dizziness or light-headedness can also occur, particularly after standing up. A person who feels affected should sit or lie down, rise slowly and avoid driving or operating machinery until they know how the medicine affects them. Alcohol may make dizziness and low blood pressure worse.

Available strengths and pack choices

Our catalogue includes Imdur extended-release tablets in 20 mg, 30 mg, 40 mg and 60 mg strengths. Available quantities range from 30 to 360 tablets, although the quantity choices vary by strength. Not every pack size is available for every strength, so the first step is to identify the exact prescribed strength and then review the quantities available for that option.

Strengths should not be treated as interchangeable ways to reach the same total dose. Combining tablets or substituting a different strength may alter how the prescribed regimen is followed, and any such change should be confirmed by the prescriber or pharmacist. The package quantity is a separate decision: it determines how many tablets are supplied, not the dose that should be taken.

Before selecting a pack, check:

• that the name is Imdur and the dosage form is an extended-release tablet;
• that the strength matches the prescribed strength exactly;
• that the quantity is appropriate for the prescribed daily schedule; and
• that the medicine will remain within its storage requirements while it is held.

This approach is more reliable than choosing the lowest price per tablet or the largest quantity without reference to the treatment plan.

When should an effect be expected?

Imdur begins releasing isosorbide mononitrate after a dose, but its value is not judged by rapid relief of active chest pain. It is intended to support prevention during the daily dosing period. The practical outcome to monitor is whether angina frequency, exertional tolerance or need for a prescribed rescue medicine changes over time, as assessed with the treating clinician.

Some adverse effects, particularly headache, flushing, dizziness or light-headedness, may be noticed early. These effects do not prove that the medicine is providing adequate angina prevention, and the absence of headache does not mean that it is ineffective. Dose changes should be based on clinical review rather than on whether a person can feel the medicine working.

An acute angina episode should be managed according to the person's existing action plan and the directions for any prescribed fast-acting medicine. If chest pain is new, severe, worsening, occurs at rest or does not settle as directed, urgent medical help is needed. In Australia, call Triple Zero (000) for an emergency.

Safety priorities before use

The most important avoidable risk is combining a nitrate with a phosphodiesterase type 5 inhibitor used for erectile dysfunction or pulmonary hypertension, such as sildenafil, tadalafil or vardenafil. The combination can cause a profound and dangerous fall in blood pressure. Soluble guanylate cyclase stimulators such as riociguat can create a similar risk and should not be combined with nitrate treatment. A prescriber or pharmacist needs to review the timing of these medicines; a person should not estimate a safe interval independently.

Imdur also requires careful assessment in people with very low blood pressure, severe anaemia, reduced circulating blood volume or conditions in which a fall in cardiac filling pressure may be harmful. The supplied product information should be checked for the full contraindications and precautions relevant to the individual. A known allergy to isosorbide mononitrate, another nitrate or any tablet ingredient also needs to be disclosed.

Pregnancy, breastfeeding and treatment in children require particular caution because safety information is limited. When starting treatment or changing dose, headache, dizziness, weakness or faintness may affect driving and other activities that require alertness. These risks are most safely reviewed before the first dose rather than after a problem occurs.

Interactions and practical precautions

Other medicines that lower blood pressure can add to the effect of isosorbide mononitrate. These include beta blockers such as metoprolol, atenolol and bisoprolol, calcium channel blockers such as amlodipine, other vasodilators, some medicines for high blood pressure and certain medicines used for mental health conditions. Such combinations may be clinically appropriate, but the prescriber may need to monitor blood pressure, dizziness and angina symptoms.

A short-acting nitrate can sometimes be prescribed alongside Imdur for acute symptom relief. This does not mean that extra nitrate doses can be added whenever desired. The products serve different purposes, and the timing and maximum use of the rescue medicine should be specified in the person's treatment plan.

Alcohol may intensify headache, dizziness and low blood pressure. A person who becomes light-headed should avoid driving, climbing or using machinery. Rising slowly from sitting or lying down can reduce postural dizziness, but recurrent faintness or fainting warrants medical advice.

Store Imdur at 25°C; excursions from 15°C to 30°C are permitted. Keep the tablets in their original packaging, protected as directed in the product information and out of the reach of children. Do not use tablets that are damaged or beyond their expiry date.

Which alternative may suit a different treatment plan?

Alternatives should be compared by clinical role, formulation and dosing needs rather than treated as direct substitutes. A prescriber may consider a different nitrate or another antianginal medicine when the release profile, adverse effects, blood pressure response or symptom pattern makes Imdur unsuitable.

These comparisons provide discussion points, not a basis for changing treatment independently. Our heart disease range places Imdur alongside medicines used for related cardiovascular needs, while our blood pressure range includes medicines whose role may overlap when high blood pressure and angina are managed together.

Australian access and prescription context

In Australia, isosorbide mononitrate is a Schedule 4 Prescription Only Medicine. Lawful Australian supply therefore requires the applicable prescription and professional oversight. The exact medicine, strength and extended-release formulation must also have the appropriate inclusion in the Australian Register of Therapeutic Goods.

Modified-release isosorbide mononitrate tablets have Pharmaceutical Benefits Scheme listings for specified angina indications. PBS eligibility, the applicable brand and any patient contribution depend on the current listing and prescription details. A PBS listing should not be assumed to apply to every pack or supply arrangement.

These Australian regulatory requirements are separate from our catalogue and ordering process. Suspected adverse reactions can be reported to the Therapeutic Goods Administration through its adverse-event reporting system, as well as discussed with a doctor or pharmacist.

Selecting and receiving the correct product

Before placing an order, match the displayed Imdur strength and tablet quantity to the prescription or treatment directions. We list prices in Australian dollars and show the available pack choices for each strength. Our pharmacist-supported team is available 24/7 by email, online chat or phone if clarification is needed about the catalogue option being selected. We have operated since 2017.

When the package is received, check the medicine name, extended-release dosage form, strength, quantity and expiry details before use. The label directions should agree with the intended regimen. If the strength, dosage form, packaging or directions appear different from what was expected, keep the medicine unused and contact our support team for clarification.

Plan quantity around the prescribed schedule and the time at which further clinical review is due. A large pack does not remove the need for blood pressure checks, review of angina control or reassessment of adverse effects. It is also sensible to monitor the remaining supply so that treatment is not stopped abruptly because the tablets have run out.

The final product decision

Imdur is most relevant when the treatment plan specifically calls for once-daily, extended-release isosorbide mononitrate for prevention of angina. Its central advantage is a consistent daily formulation, but that advantage applies only when the prescribed release type, strength and schedule are correct for the individual. It cannot replace a fast-acting medicine for chest pain already in progress.

The final selection should align four details: the Imdur name, the extended-release tablet form, one of the available 20 mg, 30 mg, 40 mg or 60 mg strengths and an appropriate package quantity. Interacting medicines - especially sildenafil, tadalafil, vardenafil or riociguat - must be reviewed before use. A person who is still adjusting treatment, experiencing low blood pressure or having new or worsening chest pain needs clinical review rather than a self-directed change in strength or formulation.